drugset / Trial / NCT04191616
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
NaSingle-groupOpen-labelTreatment
Summary
A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone
Timeline
- Start
- 2020-08-06
- Primary completion
- 2022-11-30
- Completion
- 2024-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | 56 mg/m2 | Intravenous |
| Subject | Dexamethasone | Small molecule | 10 mg | — |
| Subject | Dexamethasone | Small molecule | 20 mg | — |
| Subject | Pomalidomide | Other / unclassified | 4 mg | Oral |